Advisory Services Network LLC Makes New $768,000 Investment in BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

Advisory Services Network LLC bought a new position in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 144,900 shares of the specialty pharmaceutical company’s stock, valued at approximately $768,000. Advisory Services Network LLC owned 0.16% of BioDelivery Sciences International as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Barclays PLC boosted its stake in shares of BioDelivery Sciences International by 942.8% during the fourth quarter. Barclays PLC now owns 328,039 shares of the specialty pharmaceutical company’s stock worth $1,214,000 after buying an additional 296,582 shares during the period. Knott David M grew its position in shares of BioDelivery Sciences International by 33.8% in the fourth quarter. Knott David M now owns 500,300 shares of the specialty pharmaceutical company’s stock valued at $1,851,000 after purchasing an additional 126,300 shares during the last quarter. Close Asset Management Ltd grew its position in shares of BioDelivery Sciences International by 1,340.0% in the first quarter. Close Asset Management Ltd now owns 18,000 shares of the specialty pharmaceutical company’s stock valued at $95,000 after purchasing an additional 16,750 shares during the last quarter. 1492 Capital Management LLC grew its position in shares of BioDelivery Sciences International by 175.1% in the fourth quarter. 1492 Capital Management LLC now owns 881,788 shares of the specialty pharmaceutical company’s stock valued at $3,263,000 after purchasing an additional 561,265 shares during the last quarter. Finally, Pura Vida Investments LLC acquired a new stake in shares of BioDelivery Sciences International in the fourth quarter valued at approximately $2,305,000. Institutional investors and hedge funds own 56.73% of the company’s stock.

In other BioDelivery Sciences International news, CEO Herm Cukier sold 30,285 shares of the business’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $5.07, for a total transaction of $153,544.95. Following the completion of the transaction, the chief executive officer now directly owns 66,666 shares of the company’s stock, valued at approximately $337,996.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $4.68, for a total transaction of $37,440.00. Following the transaction, the director now directly owns 604,754 shares of the company’s stock, valued at $2,830,248.72. The disclosure for this sale can be found here. Insiders have sold a total of 2,429,743 shares of company stock valued at $11,707,558 over the last three months. 8.94% of the stock is currently owned by company insiders.

Shares of NASDAQ BDSI traded up $0.01 during midday trading on Friday, hitting $4.07. The company’s stock had a trading volume of 1,036,891 shares, compared to its average volume of 1,213,454. BioDelivery Sciences International, Inc. has a 1-year low of $2.35 and a 1-year high of $5.37. The business has a fifty day simple moving average of $4.41. The company has a debt-to-equity ratio of 1.90, a quick ratio of 2.57 and a current ratio of 2.88. The firm has a market cap of $364.31 million, a price-to-earnings ratio of -5.58 and a beta of 0.47.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Monday, May 6th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The firm had revenue of $19.77 million during the quarter, compared to analyst estimates of $19.60 million. BioDelivery Sciences International had a negative net margin of 42.09% and a negative return on equity of 43.40%. On average, equities research analysts forecast that BioDelivery Sciences International, Inc. will post -0.14 EPS for the current year.

Several analysts have recently commented on the stock. Cantor Fitzgerald set a $8.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Friday, May 10th. SunTrust Banks started coverage on shares of Zoetis in a research report on Tuesday, March 19th. They set a “hold” rating and a $100.00 target price on the stock. BidaskClub downgraded shares of Weyco Group from a “sell” rating to a “strong sell” rating in a research note on Saturday. HC Wainwright reissued a “neutral” rating on shares of Rewalk Robotics in a research note on Friday, March 15th. Finally, Zacks Investment Research downgraded shares of HENGAN INTL GRP/ADR from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 21st. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $6.20.

BioDelivery Sciences International Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Further Reading: How do candlesticks reflect price movement?

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.